Searchable abstracts of presentations at key conferences in endocrinology

ea0077p189 | Metabolism, Obesity and Diabetes | SFEBES2021

BMI category-specific waist circumference thresholds for predicting the risk of cardiometabolic diseases: A nationwide population-based study

Son Jang Won , Lee Seong-Su , Kim Sungrae , Kwon Hyuk-Sang , Jib Yoo Soon

Background: There is no existing longitudinal study to support ethnicity-specific and body mass index (BMI) category-specific waist circumference (WC) thresholds and their potential clinical utility to assess the risk of obesity-related diseases.Methods: We performed a prospective assessment of 5,852,702 subjects in large-scale population-based cohort dataset obtained from the Korea National Health Insurance System. BMI was categorized into 6 subgroups (...

ea0090p329 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

RNA-seq profiling from white adipocyte to brown adipocyte-like cells trans-differentiation of 3T3-L1 by β3-adrenergic stimulation

Jib Yoo Soon , Hong Oak-Kee , Kim Eun-Sook , Kwon Hyuk-Sang

Beige adipocytes can be induced from white adipocytes (WAT) and precursors upon stimulation by cold temperatures and act like brown adipocytes (BAT) to increase energy expenditure. Most in vivo studies examining the mechanisms for the induction of beige/brown adipocytes have focused on subcutaneous white adipose tissue (sWAT) in the mouse. To better understand the development of beige/brown adipocytes from mammalian sWAT, we induced WAT and BAT from 3T3-L1 preadipocyt...

ea0090p335 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Dapagliflozin Improves Glycemic control and Liver Function with Body Weight Loss as Add-on therapy to Metformin Plus Evogliptin: A 24-week, Randomized, Double-blind, Clinical Trial

Jeong In-Kyung , Mook Choi Kyung , Ah Han Kyung , Kim Kyoung-Ah , kim injoo , jin Han Seung , Wan Lee Byung , Lee Won-Young , Jib Yoo Soon

Background and aims: The efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control with evogliptin and metformin combinations was investigated.Materials and methods: Patients with HbA1c of 7.0% to 10.5% receiving evogliptin 5mg and metformin ≥1000 mg were randomized to receive dapagliflozin 10 mg/day (n=99) or placebo (n=99) for 24 weeks. The primary end...